GSTP1和ABCC2基因多态性对接受铂类化疗的晚期非小细胞肺癌患者治疗反应的影响：一项在中国维吾尔族人群中的研究

Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.

作者信息

Han Zhi-Gang, Tao Jie, Yu Ting-Ting, Shan Li

机构信息

Department of Thoracic Oncology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China (mainland).

出版信息

Med Sci Monit. 2017 Apr 26;23:1999-2006. doi: 10.12659/msm.904156.

DOI:10.12659/msm.904156

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5414593/

Abstract

BACKGROUND Gene polymorphisms are associated with sensitivity to platinum drugs. This study aimed to investigate the polymorphisms of GSTP1 rs1695 locus and ABCC2 rs717620 locus, and the sensitivity of patients with advanced non-small cell lung cancer (NSCLC) to platinum drugs in a Xinjiang Uygur population. MATERIAL AND METHODS The gene polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 of Uygur NSCLC patients were assessed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The relationship between the prognosis of advanced NSCLC Uygur patients and the gene polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 was analyzed using progression-free survival (PFS) and overall survival (OS) as the major outcome indicators. RESULTS The median PFS of patients with advanced NSCLC was 6.9 months and the OS of Uygur patients with advanced NSCLC was 10.8 months. Kaplan-Meier survival analysis indicated that survival time of patients with GSTP1 AG + GG was significantly longer than in patients with AA gene (P<0.05), and survival time of patients with ABCC2 CT + TT was significantly longer than in patients with the CC gene (P<0.05). CONCLUSIONS Polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 can be used to predict the outcomes of Uygur patients with advanced NSCLC who have received platinum-based chemotherapy. Additionally, this information could be used to guide the individualized treatment of Uygur patients with advanced NSCLC.

摘要

背景基因多态性与铂类药物敏感性相关。本研究旨在调查新疆维吾尔族人群中晚期非小细胞肺癌（NSCLC）患者谷胱甘肽S-转移酶P1（GSTP1）基因rs1695位点和ATP结合盒转运体C2（ABCC2）基因rs717620位点的多态性，以及患者对铂类药物的敏感性。

材料与方法采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法检测维吾尔族NSCLC患者GSTP1基因rs1695和ABCC2基因rs717620的基因多态性。以无进展生存期（PFS）和总生存期（OS）作为主要观察指标，分析晚期NSCLC维吾尔族患者预后与GSTP1基因rs1695和ABCC2基因rs717620多态性的关系。

结果晚期NSCLC患者的中位PFS为6.9个月，晚期NSCLC维吾尔族患者的OS为10.8个月。Kaplan-Meier生存分析表明，GSTP1基因AG+GG型患者的生存时间显著长于AA基因型患者（P<0.05），ABCC2基因CT+TT型患者的生存时间显著长于CC基因型患者（P<0.05）。

结论 GSTP1基因rs1695和ABCC2基因rs717620的多态性可用于预测接受铂类化疗的维吾尔族晚期NSCLC患者的预后。此外，该信息可用于指导维吾尔族晚期NSCLC患者的个体化治疗。